Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors

Title: Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors
Authors: Golder, Anya; Nelson, Louisa; Tighe, Anthony; Barnes, Bethany; Coulson-Gilmer, Camilla; Morgan, Robert D; McGrail, Joanne C; Taylor, Stephen S
Contributors: Irshad Akhtar Memorial PhD Scholarship; Cancer Research UK Manchester Centre; Cancer Research UK Programme
Source: NAR Cancer ; volume 4, issue 4 ; ISSN 2632-8674
Publisher Information: Oxford University Press (OUP)
Publication Year: 2022
Description: High-grade serous ovarian cancer (HGSOC) is an aggressive disease that typically develops drug resistance, thus novel biomarker-driven strategies are required. Targeted therapy focuses on synthetic lethality—pioneered by PARP inhibition of BRCA1/2-mutant disease. Subsequently, targeting the DNA replication stress response (RSR) is of clinical interest. However, further mechanistic insight is required for biomarker discovery, requiring sensitive models that closely recapitulate HGSOC. We describe an optimized proliferation assay that we use to screen 16 patient-derived ovarian cancer models (OCMs) for response to RSR inhibitors (CHK1i, WEE1i, ATRi, PARGi). Despite genomic heterogeneity characteristic of HGSOC, measurement of OCM proliferation was reproducible and reflected intrinsic tumour-cell properties. Surprisingly, RSR targeting drugs were not interchangeable, as sensitivity to the four inhibitors was not correlated. Therefore, to overcome RSR redundancy, we screened the OCMs with all two-, three- and four-drug combinations in a multiple-low-dose strategy. We found that low-dose CHK1i-ATRi had a potent anti-proliferative effect on 15 of the 16 OCMs, and was synergistic with potential to minimise treatment resistance and toxicity. Low-dose ATRi-CHK1i induced replication catastrophe followed by mitotic exit and post-mitotic arrest or death. Therefore, this study demonstrates the potential of the living biobank of OCMs as a drug discovery platform for HGSOC.
Document Type: article in journal/newspaper
Language: English
DOI: 10.1093/narcan/zcac036
Availability: https://doi.org/10.1093/narcan/zcac036; https://academic.oup.com/narcancer/article-pdf/4/4/zcac036/47013035/zcac036.pdf
Rights: https://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.FB4EC2A
Database: BASE